Aastrom gets go-ahead to continue Phase IIb trial of heart drug


The independent Data & Safety Monitoring Board for the Phase IIb trial of Aastrom Biosciences' (ASTM) ixmyelocel-T for the treatment of advanced heart failure has recommended that the study continue without any changes.

The recommendation follows an interim review of safety data.

Aastrom expects to complete enrollment for the trial in H2.

Shares are +6.5%. (PR)

From other sites
Comments (1)
  • Jérôme Verony
    , contributor
    Comments (165) | Send Message
     
    good news!
    9 Apr 2014, 09:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs